The effects of the co-administration of the α1-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 107-111

  Takamura, Naoki ^a,b   Masuda, Takahiro ^a,b   Inoue, Takeshi ^a   Nakagawa, Shin ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Anxiety; Conditioned fear; Prazosin; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; PRAZOSIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEAR; FREEZING BEHAVIOR; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; RAT; STRESS; TRANQUILIZING ACTIVITY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTI-ANXIETY AGENTS; CITALOPRAM; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEAR; MALE; MOTOR ACTIVITY; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 84864516719     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.017     Document Type: Article

References (36)

1. Amargos-Bosch M., Artigas F., Adell A. Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 2005, 516:235-238.
2. Bandelow B., Zohar J., Hollander E., Kasper S., Moller H.J., Allgulander C., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008, 9:248-312.
3. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980, 19:355-363.
4. Baraban J.M., Aghajanian G.K. Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res 1981, 204:1-11.
5. Borsini F., Podhorna J., Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology 2002, 163:121-141.
6. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002, 160:353-361.
7. Den Boer J.A., Westenberg H.G. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988, 3:59-74.
8. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994, 55:163-167.
9. Gillman P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007, 151:737-748.
10. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998, 84:413-429.
11. Hashimoto S., Inoue T., Koyama T. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berl) 1996, 123:182-186.
12. Hjorth S., Bengtsson H.J., Milano S., Lundberg J.F., Sharp T. Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release-I. BMY7378 and prazosin. Neuropharmacology 1995, 34:615-620.
13. Inoue T., Hashimoto S., Tsuchiya K., Izumi T., Ohmori T., Koyama T. Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing. Eur J Pharmacol 1996, 311:1-6.
14. Inoue T., Kitaichi Y., Koyama T. SSRIs and conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1810-1819.
15. Inoue T., Li X.B., Abekawa T., Kitaichi Y., Izumi T., Nakagawa S., et al. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol 2004, 497:311-316.
16. 1-adrenergic receptor. Pharmacol Biochem Behav 2009, 92:393-398.
17. Koch S., Perry K.W., Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004, 46:232-242.
18. Lam R.W., Kennedy S.H., Grigoriadis S., McIntyre R.S., Milev R., Ramasubbu R., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117(Suppl. 1):S26-S43.
19. Lejeune F., Audinot V., Gobert A., Rivet J.M., Spedding M., Millan M.J. Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. Eur J Pharmacol 1994, 260:79-83.
20. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993, 112:S40-S54.
21. Menkes D.B., Baraban J.M., Aghajanian G.K. Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 1981, 317:273-275.
22. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001, 298:565-580.
23. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
24. Nishitsuji K., To H., Shimizu T., Yanase Y., Yamada T., Hara C., et al. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur Neuropsychopharmacol 2006, 16:376-382.
25. Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegaard J., et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995, 167:374-379.
26. Ohmori T., Abekawa T., Muraki A., Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol Biochem Behav 1994, 48:587-591.
27. 2 adrenoceptors. Synapse 2003, 50:77-82.
28. 1-Adrenoceptors modulate citalopram-induced serotonin release. Neuropharmacology 2010, 58:962-971.
29. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
30. Rouquier L., Claustre Y., Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994, 261:59-64.
31. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
32. 1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav 2007, 86:622-630.
33. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998, 51:215-235.
34. Vandermaelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 1983, 289:109-119.
35. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23:250-262.
36. Zohar J., Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000, 403:39-49.